Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia
Latest BioSpace coverage of Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric
Amylyx Pharmaceuticals
AMLX $32.39 USD
Biopharmaceutical company. Small Molecule Pharma